Alligator aims at carrying out risk assessment.
Alligator Bioscience and AlgoNomics entered into a collaboration in which the latter will employ its Epibase® platform to complement the former in the optimization of therapeutic proteins both in their internal projects and in collaborative projects with customers.

“All proteins delivered as biopharmaceuticals could render an immune response. For Alligator it is of great importance to make a responsible risk assessment on any new project. We are therefore grateful to be able to work with AlgoNomics, delivering a state-of-the-art technology, for investigating the theoretical consequence of an immune response,” states Gun-Britt Fransson, CEO of Alligator Bioscience.

The collaboration allows Alligator to maximally reduce immunogenicity upon optimization of protein therapeutics with its ssDNA recombination technology FIND®.

Previous articleDSM Biologics Provides Manufacturing Services to Argenes
Next articleLexicon Genetics Grant Extended by One-Year to Study Spinal Muscular Atrophy